Page 3 - Signum Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Signum biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Signum Biosciences Today - Breaking & Trending Today

Willow Biosciences Announces Ground-Breaking Scientific Data for Cannabigerol (CBG) on Human Skin


 Willow Biosciences Inc. (
Willow or the
Company ) (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow s cannabigerol (
Willow
CBG ). The studies demonstrate that Willow CBG is safe when applied to skin and eye areas and can act as a more potent antioxidant and anti-inflammatory for certain skin applications when compared to plant derived cannabidiol (
CBD ), as further described below.
Demonstrating the safety and benefit of a new ingredient like Willow s CBG is a critical step in commercialization and it s one that we take seriously at the Company, said Dr. Chris Savile, Willow s Chief Operating Officer. Willow s CBG is now clinically tested to be safe for sensitive skin and demonstrated in the laboratory to act as a potent antioxidant, anti-inflam ....

British Columbia , United Kingdom , Chris Savile , Willow Biosciences Inc , Society For Investigative Dermatology , Signum Biosciences Inc , Signum Bioscience Inc , Willow Biosciences , Signum Biosciences , Chief Operating , Human Repeat Insult Patch Test , Normal Human Epidermal Keratinocytes , Human Dermal Fibroblasts , Investigative Dermatology , Signum Bioscience , பிரிட்டிஷ் கொலம்பியா , ஒன்றுபட்டது கிஂக்டம் , கிறிஸ் மிருகத்தனமான , வில்லோ உயிர் அறிவியல் இன்க் , சமூகம் க்கு விசாரணை தோல் நோய் , சிக்னம் உயிர் அறிவியல் இன்க் , வில்லோ உயிர் அறிவியல் , சிக்னம் உயிர் அறிவியல் , தலைமை இயங்குகிறது , விசாரணை தோல் நோய் ,

Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment


Willow Biosciences Provides Update on Cannabigerol Research Studies and Key Personnel Appointment
News provided by
Share this article
Willow or the
Company ) (TSX: WLLW) (OTCQX: CANSF) is pleased to announce that it is undertaking two initiatives to help our customers evaluate and better understand cannabigerol (
CBG ), our first commercial cannabinoid slated for production in Q1 2021.
Willow has engaged Signum Biosciences, a leading biopharmaceutical company focused on the discovery and development of innovative consumer products, to generate a robust safety and data package for our CBG to demonstrate its safety and activity as a cosmetic ingredient.  The Company has also engaged a world-renowned regulatory consulting group to perform a comprehensive safety assessment to independently conclude that our CBG is Generally Regarded As Safe (GRAS) for use as an ingredient in food and beverage products and support future novel food submissions in multiple ....

United States , United Kingdom , British Columbia , Mountain View , Signum Biosciences , Chris Savile , Trevor Peters , Willow Biosciences Inc , Research Development , Willow Biosciences , Generally Regarded As Safe , Chief Executive , Mathias Schuetz , Vice President , Trish Choudhary , Senior Director , Strain Engineering , Chief Operating , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா , மலை பார்வை , சிக்னம் உயிர் அறிவியல் , கிறிஸ் மிருகத்தனமான , ட்ரெவர் பீட்டர்ஸ் , வில்லோ உயிர் அறிவியல் இன்க் ,